Emergent BioSolutions, Inc. hosts biomedical symposium

Emergent BioSolutions, Inc., recently hosted a symposium with the NIH-Oxford-Cambridge Scholars Program at the company’s product development facility in Gaithersburg, Maryland.
The goal of the gathering was to demonstrate potential employment opportunities and areas of research within the biomedical industry. Areas of focus included intellectual property, clinical development and product development. After the symposium, the scholars were given a tour of the company’s facilities.

"Emergent is pleased to welcome the future leaders in scientific research and discovery, who are already engaged in and contributing to public health improvement by exhibiting academic excellence," Fuad El-Hibri, chairman and CEO of Emergent BioSolutions, Inc., and member of the Alliance Board of Trustees said. "We congratulate them for their exceptional talent, which brought them to the scholars program and which will guide them to its completion."
The NIH-Oxford-Cambridge Scholars Program is an accelerated doctoral program that provides students with two mentors - one at NIH and another at either Oxford or Cambridge. The program is designed to be intensive and collaborative and prepare scholars for global challenges within the biomedical industry.
Since it’s inception in 2001, the program's students have been published in over 40 publications, including Nature and The Journal of Experimental Medicine. There are currently 113 students enrolled in the program.